Among breast cancer patients, those exhibiting overexpression of Human Epidermal Growth Factor Receptor 2 (HER2), accounting for approximately 20–25% of the cases, tend to have a poorer prognosis compared to patients who are HER2-negative [5–7]. Here, ERBB2 is linked to breast carcinoma.